Law Offices of Howard G. Smith announces that it is investigating
potential claims against the Board of Directors of Human Genome Sciences
Inc. (“Human Genome” or the “Company”) (NASDAQ: HGSI) related to the
proposed acquisition of the Company by GlaxoSmithKline PLC. The
transaction is valued at approximately $3.6 billion or $14.25 per share.
This investigation concerns whether the Board of Directors of Human
Genome breached their fiduciary duties to stockholders by failing to
adequately shop the Company before agreeing to enter into the proposed
transaction, and whether the Company has disclosed all material
information to shareholders about the transaction. The Company has seen
substantial recent growth. Further, at least one analyst has set a
target price for the Company’s stock at $23.00.
If you are a shareholder of Human Genome, if you have information or
would like to learn more about our investigation, or if you wish to
discuss these matters or have any questions concerning this announcement
or your rights or interests with respect to these matters, please
contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone
at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at http://www.howardsmithlaw.com.
